On 13 November 2026 our catalogue included about 26,000 products with at least one variant whose ingredient list names Tocopheryl Acetate. It is the acetic acid ester of tocopherol, used as an antioxidant and a skin-conditioning agent. The CIR conclusion is in the safety section. Tocopherol is a different INCI: the free form, with the phenol that the acetate blocks.
Tocopheryl acetate (INCI: Tocopheryl Acetate, CAS 7695-91-2, EC 231-710-0 / 200-405-4) is the ester formed when acetic acid is attached to the phenol of tocopherol. The catalogue lists the functions antioxidant and skin conditioning, and the formula C31H52O3. Those function labels describe a role in a formula. They are not a claim that the ingredient treats a named skin disease. This page is about topical cosmetic use.
It is not tocopherol. Tocopherol is the free form: the phenol is open. Tocopheryl acetate is that phenol acetylated. The names are not substitutes on a label. A product that lists Tocopherol does not, by that name, contain Tocopheryl Acetate, and the reverse is also true. Searches for one often land on the other because both are sold as vitamin E.
The acetate is the more storage-stable of the two. The SCCNFP opinion of 25 September 2001 says the native compound, alpha-tocopherol, has limited stability at room temperature, which is why the esters are used in sunscreen and skin-care products. Acetylation also blocks the phenol, so the ester does not do the same radical-scavenging job as free tocopherol until some of it is converted back.
Conversion in skin happens, and it is limited and depends on the vehicle. The 2014 CIR report summarises Baschong and colleagues (Journal of Cosmetic Science, 2001) in Table 6, an ex vivo study on viable human skin. In this ex vivo study, approximately 35–51% of the recovered vitamin E material in the underlying skin was present as free tocopherol, depending on the vehicle and application conditions. This percentage does not represent conversion of the total applied dose. Non-occlusive application favoured greater deposition in the underlying skin, whereas occlusion generally increased the proportion converted within that layer. In a triglyceride oil, the ester almost entirely remained as the ester, on the surface and in the horny layer. That is one ex vivo study. It is not a percentage for every cream on the market. A mouse-skin experiment summarised in the same report found hydrolysis under 1% of the applied dose in that protocol. The two results are not the same experiment.
The 2014 CIR report describes manufacture this way: tocopherol is isolated on a commercial scale from vegetable oils, and it is also produced synthetically, in which case a racemic mixture of eight stereoisomers is formed. Tocopheryl acetate is prepared by esterifying tocopherol with acetic acid. CosIng lists two CAS numbers for this INCI. CAS 58-95-7, EC 200-405-4, is RRR-alpha-tocopheryl acetate. CAS 7695-91-2, EC 231-710-0, is all-rac-alpha-tocopheryl acetate. RRR-alpha-tocopheryl acetate is commonly associated with natural-source vitamin E, whereas all-rac-alpha-tocopheryl acetate is commonly produced synthetically. The INCI name alone does not establish stereoisomer composition or raw-material provenance.
It is tocopherol with an acetate on the phenol. That is why the INCI is Tocopheryl Acetate and not Tocopherol. The ester is a different ingredient.
The catalogue and CosIng list an antioxidant function. The acetate is chosen because it keeps better than free tocopherol. It is not the free phenol. The acetate lacks the free phenolic group needed for tocopherol's direct radical-scavenging activity. Its potential antioxidant contribution in skin depends partly on conversion to free tocopherol, which varies with the vehicle and application conditions. An INCI function listing does not establish the clinical benefit of a finished product.
The catalogue lists skin conditioning. That is a label for how a formula is meant to leave the skin feeling. The amount in a given product is not on the INCI list.
Where it shows up: on 13 November 2026, among about 26,000 products in our catalogue, it appears in moisturisers, serums, sunscreens, cleansers, face masks, body lotions, shampoos, eye care, lipsticks, and nail products. The cards below use the full product name and the kind of product that name describes.
Tocopheryl acetate and tocopherol are compared here on the molecule, the label, and what skin does with the ester. Many searches for one open the page for the other.
| Tocopheryl acetate | Tocopherol | |
|---|---|---|
| What it is | The acetic acid ester of tocopherol. C31H52O3. The phenol is acetylated. | The free form. The phenol is open. Several tocopherols share the INCI Tocopherol. The tocopherol page is the page for that name. |
| On a label | The INCI name is Tocopheryl Acetate. 生育酚乙酸酯. Vitamin E acetate is a common English name, not a second INCI. | The INCI name is Tocopherol. A list that says Tocopherol is not, by that word, listing the acetate. |
| Stability and the skin | More storage-stable than free tocopherol. Skin esterases convert some of it back. In an oil, most of the recovered material was still the acetate, on the surface and in the horny layer. | The free phenol is the form that scavenges radicals without waiting for hydrolysis. It is also the less storage-stable form, which is why many formulas use the ester. |
The EU CosIng entry for Tocopheryl Acetate, ref. 38627, was checked against the current official entry on 13 November 2026. The functions listed are antioxidant and skin conditioning. A CosIng listing names functions. It is not an approval, and it is not evidence about safety.
On 13 November 2026 the current entry showed no annex reference linked. That is what the entry displayed on that date. It is not a claim that no sentence in an annex could ever touch a raw material sold under this name. The SCCNFP opinion of 2001 said alpha-tocopherol and its derivatives were not, at that time, subject to a particular rule in the annexes of Directive 76/768/EEC, and use fell under the general requirement that a product must not cause damage to health. That is the committee’s statement about the directive then in force. It is not a fresh reading of every annex line in 2026.
The CIR conclusion and this rating are different things. The CIR text conclusion is set out in the card below. The SCCNFP opinion of 2001 is a separate text conclusion.
The number in the circle is this site’s hazard-signal rating. Tocopheryl Acetate is on a fixed list of familiar ingredients with a set value; for listed names that value takes precedence, hazard codes are not read and no restriction add-on applies. The number is not calculated from the toxicology studies, case reports, patch-test data, or H413 cited on this page. There is no scientific basis on this page for treating 1 versus 2, or any other exact value, as meaningful. Readers should rely on the CIR and SCCNFP conclusions and on the allergy and environmental sections, which are presented independently. It is a rule-based classification. It is not a percentage of risk, and it is not a judgement on any single product. How our hazard-signal rating works.
Fiume and colleagues (International Journal of Toxicology, 2018) is the published form of the CIR final amended report released on 4 April 2014. The conclusion covers 14 tocopherols and tocotrienols, tocopheryl acetate among them: safe in the present practices of use and concentration described in that assessment. The earlier final report, from 2002, had already reached that conclusion for tocopheryl acetate. The 2014 report is the re-review, and it is the current CIR conclusion. The wording is a text conclusion. It is not a numeric level, and it is not this site’s hazard-signal rating.
Table 4 is the scope. FDA VCRP data for 2014 give 9,677 uses, of which 9,098 are reported as tocopheryl acetate and 579 as tocopheryl acetate dl-alpha. A 2013 industry survey gives a concentration range of 0.00000001–36%. The leave-on maximum of 36% is the nail figure: nail products were reported at 0.002–36%. Dermal contact was reported at 0.000045–5%. Rinse-off was reported up to 10%. Eye-area products were reported up to 4.9%. Baby products were reported at 0.001–0.1%. Those figures are category survey values, not the percentage in a reader’s product, and not a legal limit. They are also not our catalogue’s about 26,000 products.
The Panel said irritation and sensitisation data available since the 2002 review indicate that tocopheryl acetate is not an irritant or a sensitiser, and that the irritation and sensitisation potentials of this ingredient group were not of concern. That sentence sits next to published case reports, which are set out below. The Panel’s conclusion is what it said after the data it reviewed. It is not a finding that no person has ever reacted.
CIR says it is funded by the Personal Care Products Council, and that CIR, the Expert Panel for Cosmetic Ingredient Safety, and the review process are independent from the Council and the cosmetics industry. The US FDA describes CIR as an industry-funded panel of scientific and medical experts. The FDA says it participates in CIR meetings but does not vote, that it may agree or disagree with CIR conclusions, and that it takes CIR reviews into consideration when it evaluates cosmetic ingredient safety.
SCCNFP/0494/01, adopted on 25 September 2001, is the opinion of the EU scientific committee that preceded the SCCS. The committee was asked whether the documented profile supported a statement that alpha-tocopherol acetate poses a significant threat to the consumer, and whether it proposed any restrictions. The question was prompted by a mouse study in which the acetate, applied in acetone, did not prevent photocarcinogenesis and was reported as possibly enhancing tumours. The committee said the biological relevance of that animal experiment for human health was questionable because of experimental shortcomings, and that other toxicological data did not support those animal findings. Its opinion was that, on the knowledge then available, alpha-tocopherol acetate does not pose a threat to the health of the consumer, and it proposed no restrictions or conditions of use.
That opinion does not set a cosmetic concentration. It is not an SCCS opinion, and this page did not find a later SCCS opinion that replaces it or that sets a limit for this ingredient. The CIR table above is the later account of surveyed cosmetic concentrations.
Irritation, becoming sensitised and then reacting on contact, and immediate hypersensitivity are different events. A positive patch test is a test result. It is not, by itself, the same thing as a clinical reaction the patient is having, and the studies below judge relevance separately when they judge it at all. This page does not rank exposure routes. The data below are about skin contact.
The CIR report’s reading of the irritation and sensitisation studies is the sentence in the CIR card: the data indicated that tocopheryl acetate is not an irritant or a sensitiser, and the Panel did not treat the potential as a concern for cosmetic use at the surveyed concentrations. Case reports still exist. de Groot and colleagues (Contact Dermatitis, 1991) reported four patients with cosmetic allergy and positive patch tests to tocopheryl acetate. Those are case reports, not a rate. The test concentration is under Further reading.
Warshaw and colleagues (Dermatitis, 2021) reviewed North American Contact Dermatitis Group tests from 2001 to 2016. The paper was published after the 2014 CIR assessment and was not part of the data CIR reviewed. Of 38,699 patients tested with dl-alpha-tocopherol 100% and/or dl-alpha-tocopherol acetate 100%, 349 reacted, 0.9%. Of those positive reactions, 87.6% were judged currently clinically relevant, and 51.4% were weak. The authors describe positive reactions as relatively rare given how widely these ingredients are used. The 0.9% is a frequency in patch-tested dermatitis patients, not a rate for people in general, and the series does not split the free form from the acetate. The tocopherol page is where the free-form screening cycles are set out. A positive patch test in that series is not a result about immediate hypersensitivity.
The 1990s outbreak that the 2002 CIR report discussed was traced to tocopheryl linoleate, a different ester, not to tocopheryl acetate. Mixing the two esters is how that outbreak gets misread as an acetate finding.
H413 is reported in ECHA C&L notifications for one listed identity. The CLP wording is “may cause long lasting harmful effects to aquatic life.” That environmental hazard is a separate question from skin safety. Article 1(5) of Regulation (EC) No 1272/2008 provides that CLP hazard classification does not apply to finished cosmetics intended for the final user.
Use levels in the 2014 table: The 2013 concentration-of-use bands are in the CIR card above, including nail products, dermal contact, rinse-off, the eye area, and baby products. They are unpublished data submitted for the CIR assessment. They are not the percentage in a reader’s jar, and not a legal cap. The 2014 reaffirmation points at those practices of use, not at an unlimited concentration.
Further reading: In the clinical test the CIR report cites, a cuticle softener containing 36% tocopheryl acetate was essentially non-irritating in a single-insult occlusive patch test in 19 subjects. Undiluted dl-alpha-tocopheryl acetate was reported as not a sensitiser in a human study summarised from an ECHA robust summary. Those concentrations belong to those tests. They are not a licence to read every product as 36%, and they are not the dermal-contact maximum in the 2013 survey. de Groot and colleagues patch tested tocopheryl acetate at 10% in petrolatum in the four cases from 1991. The NACDG materials in the 2001–2016 series were undiluted dl-alpha-tocopherol and/or undiluted dl-alpha-tocopherol acetate. Undiluted test material is not the concentration in a moisturiser. PubChem CID 2117 is dl-alpha-tocopheryl acetate. The GHS section, read on 13 November 2026 at 11:23 UTC, shows two separate ECHA notification sets, and this page does not add them together. For EC 231-710-0, PubChem gives 1,939 reports from 5 notifications: 1,849 of 1,939 do not meet GHS hazard criteria, and 90 of 1,939, from one notification, include hazard codes that PubChem does not name, because it only displays codes above 10%. For a different EC number, 692-041-1, PubChem gives 11 reports from 1 notification and names H413. Notifications for different CAS or EC identities are not pooled into one percentage. Those shares of notifications are not a probability of harm from using a product. This page does not treat the unnamed codes in the 90 reports as H413.
Other uses: Oral vitamin E supplements, and food use of alpha-tocopheryl acetate as a nutrient, are outside this page. The CIR report set oral supplement epidemiology aside for cosmetic use because it expected systemic exposure from cosmetics to be lower than from supplements, and it called that epidemiology inconclusive. That is not a pregnancy finding. Separately, vitamin E acetate in lung fluid was associated with e-cigarette, or vaping, product use-associated lung injury (Blount and colleagues, New England Journal of Medicine, 2020). That association is about inhalation, not about a cream or a serum left on the skin.
The 2014 CIR report and the 2001 SCCNFP opinion do not tell people to avoid cosmetic tocopheryl acetate in pregnancy or while breastfeeding, and they do not set a cosmetic concentration just for pregnancy or breastfeeding. Not advising avoidance is not a pregnancy-specific assessment. The sources cited on this page are not enough to quantify risk from cosmetic use during pregnancy or breastfeeding. This page does not estimate that risk from a cream, a sunscreen, or a serum. Someone who is pregnant or breastfeeding and wants advice about a specific product should ask their own clinician.
Look for the INCI name Tocopheryl Acetate. Tocopherol is the other ingredient. Labels may also show vitamin E acetate, acetato de tocoferilo, 生育酚乙酸酯, 醋酸生育酚, 酢酸トコフェロール, or 토코페릴아세테이트. The Japanese name follows JCIA, and the Korean name follows KCID. Under Regulation (EC) No 1223/2009, Article 19(1)(g), ingredients are listed in descending order of weight when they are added, and ingredients below 1% may be listed in any order after the ones at or above 1%. A position near the end does not reveal the percentage. The INCI name alone does not establish stereoisomer composition or raw-material provenance.
On 13 November 2026 our catalogue included about 26,000 products with at least one variant whose ingredient list names Tocopheryl Acetate. A product is counted once. The count is a usage figure for this catalogue, not evidence of safety. The cards are a selection. Each card uses the full product name and the kind of product that name describes.
The free form of vitamin E, and a different INCI. The comparison table is above.
Another antioxidant that often appears on the same lists. This page does not claim that the two protect each other in a finished product.
Listed for skin conditioning, and a common companion on serum and moisturiser lists. Sharing a list is not a finding that the pair suits every person.
An emollient often listed beside vitamin E.